CRYOFOCUS-B (06922) Sets 27 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express
Mar 17

Cryofocus Medtech (Shanghai) Co., Ltd. (CRYOFOCUS-B, 06922) has announced that its board of directors will convene on 27 March 2026. The agenda includes:

1. Reviewing and approving the Group’s audited financial results for the financial year ended 31 December 2025.

2. Deciding on the publication of the annual results announcement.

3. Considering a recommendation for the payment of a final dividend, if any.

The board currently comprises three executive directors—Mr. Li Kejian (Chairman), Mr. Zhu Jun and Mr. Liu Wei—two non-executive directors—Mr. Lv Shiwen and Mr. Zhao Chunsheng—and four independent non-executive directors—Dr. Gao Dayong, Mr. Liang Hsien Tse Joseph, Dr. Qin Zheng and Dr. Hu Henan.

The company released the notification in Hong Kong on 17 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10